[go: up one dir, main page]

GB202107706D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
GB202107706D0
GB202107706D0 GBGB2107706.0A GB202107706A GB202107706D0 GB 202107706 D0 GB202107706 D0 GB 202107706D0 GB 202107706 A GB202107706 A GB 202107706A GB 202107706 D0 GB202107706 D0 GB 202107706D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2107706.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADC Therapeutics SA
MedImmune Ltd
Original Assignee
ADC Therapeutics SA
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADC Therapeutics SA, MedImmune Ltd filed Critical ADC Therapeutics SA
Priority to GBGB2107706.0A priority Critical patent/GB202107706D0/en
Publication of GB202107706D0 publication Critical patent/GB202107706D0/en
Priority to PCT/EP2022/063158 priority patent/WO2022248268A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
GBGB2107706.0A 2021-05-28 2021-05-28 Combination therapy Ceased GB202107706D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2107706.0A GB202107706D0 (en) 2021-05-28 2021-05-28 Combination therapy
PCT/EP2022/063158 WO2022248268A1 (en) 2021-05-28 2022-05-16 Combination therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2107706.0A GB202107706D0 (en) 2021-05-28 2021-05-28 Combination therapy

Publications (1)

Publication Number Publication Date
GB202107706D0 true GB202107706D0 (en) 2021-07-14

Family

ID=76741178

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2107706.0A Ceased GB202107706D0 (en) 2021-05-28 2021-05-28 Combination therapy

Country Status (1)

Country Link
GB (1) GB202107706D0 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"Genbank", Database accession no. CAA78163
ANGEW CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186
CARTER, P., NATURE REVIEWS IMMUNOLOGY, vol. 6, 2006, pages 343 - 357
CAS , no. 391210-10-9
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
FLYNN ET AL., MOL CANCER THER, 2016
HAMANN P., EXPERT OPIN. THER. PATENTS, vol. 15, no. 9, 2005, pages 1087 - 1103
JANEWAY, C.TRAVERS, P.WALPORT, M.SHLOMCHIK: "Immuno Biology", 2001, GARLAND PUBLISHING
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOVTUN ET AL., CANCER RES., vol. 66, no. 4, 2006, pages 2328 - 2337
KS PEGGS ET AL., CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 157, 2009, pages 9 - 19
LAMBERT J, CURRENT OPIN. IN PHARMACOL., vol. 5, 2005, pages 543 - 549
LONBERG, CURR. OPINION, vol. 20, no. 4, 2008, pages 450 - 459
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212
SYRIGOSEPENETOS, ANTICANCER RESEARCH, vol. 19, 1999, pages 605 - 614
TRAIL ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337
WU ET AL., NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1137 - 1145
XIE ET AL., EXPERT. OPIN. BIOL. THER., vol. 6, no. 3, 2006, pages 281 - 291
ZAMMARCHI ET AL., AACR ANNUAL MEETING, 14 April 2018 (2018-04-14)

Similar Documents

Publication Publication Date Title
IL304223A (en) Combination therapy
IL319599A (en) Combination therapy
GB202103164D0 (en) Therapy
GB202004189D0 (en) Combination therapy
GB202002639D0 (en) Therapy
IL318268A (en) Combination therapy
GB202111288D0 (en) Combination therapy
GB202104037D0 (en) Combination therapy
GB202111035D0 (en) Therapy
GB202108303D0 (en) Therapy
GB202109373D0 (en) Combination therapy
GB202109375D0 (en) Combination therapy
GB202109377D0 (en) Combination therapy
GB202107824D0 (en) Combination therapy
GB202107709D0 (en) Combination therapy
GB202107713D0 (en) Combination therapy
GB202107706D0 (en) Combination therapy
GB202015916D0 (en) Combination therapy
GB202012161D0 (en) Combination therapy
GB202009178D0 (en) Combination therapy
GB202117706D0 (en) Therapy
GB202109893D0 (en) PeptiBAC therapy
GB202104427D0 (en) Therapy
GB202102211D0 (en) PeptiBAC therapy
GB202019218D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)